Genta's Chief Technical Officer Provides Clinical and Manufacturing Update as Keynote Speaker to Industry Conference

    BERKELEY HEIGHTS, N.J., April 26 /PRNewswire Interactive News Release/ --
 Genta Incorporated (Nasdaq:   GNTA) reported that Dr. Robert E. Klem,
 Vice-President and Chief Technical Officer, delivered the keynote address
 today at the TIDES Oligonucleotide and Peptide Technology Conference this
 morning in Tucson, AZ.  In his presentation, Dr. Klem updated preclinical,
 clinical, and manufacturing issues regarding Genta's second and third
 generation oligonucleotide research programs, which encompass drugs that use
 both antisense and "decoy" mechanisms.
     Regarding the clinical program for Genasense(TM), Genta's lead antisense
 drug, Dr. Klem noted: "Patient accrual to our lead studies is strong, which
 reflects both high investigator enthusiasm and strong interest by the medical
 community.  We continue to anticipate completing enrollment in the melanoma
 study later this year.  Although I perceive that external interest has mostly
 focused on our melanoma trial, in fact our other lead programs may also
 conclude on roughly the same timeline.  Thus, at this point, I believe our
 first NDA for Genasense(TM) -- which remains on track for filing during the
 first half of 2002 -- could be submitted from any one of our 'registration
 quality' programs."
     Regarding manufacturing issues, Dr. Klem observed: "In our clinical
 development program and looking forward to next year's anticipated launch of
 Genasense(TM), Genta is strongly advantaged by our strategic partnership with
 the Life Sciences group at Avecia Ltd., the world's largest manufacturer of
 such compounds.  Manufacturing quality has been a key issue for FDA, and as
 the company with the first antisense product intended for systemic use, Genta
 has anticipated a high level of regulatory scrutiny.  We are very pleased with
 the Avecia collaboration, and both parties remain committed to establishing
 the highest quality standards in our manufacturing processes of this product."
     Genta Incorporated is a biopharmaceutical company with a diversified
 product portfolio that is focused on anticancer therapy.  Genasense(TM), the
 Company's lead antisense compound, is currently in several Phase 3 clinical
 trials.  Genta's product pipeline also comprises a portfolio of small
 molecules, including gallium-containing compounds for treatment of diseases
 associated with accelerated bone loss, and Androgenics compounds for prostate
 cancer.  Genta aims to become a direct marketer of its pharmaceutical products
 in the United States.  For more information about Genta, please visit their
 website at: http://www.genta.com.
 
     The statements contained in this press release that are not historical are
 forward-looking statements within the meaning of Section 27A of the Securities
 Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
 1934, as amended, including statements regarding the expectations, beliefs,
 intentions or strategies regarding the future.  Without limiting the
 foregoing, the words "anticipates," "believes," "expects," "intends," "may"
 and "plans" and similar expressions are intended to identify forward-looking
 statements.  The Company intends that all forward-looking statements be
 subject to the safe harbor provisions of the Private Securities Litigation
 Reform Act of 1995.  These forward-looking statements reflect the Company's
 views as of the date they are made with respect to future events, but are
 subject to many risks and uncertainties, which could cause the actual results
 of the Company to differ materially from any future results expressed or
 implied by such forward-looking statements.  For example, the results obtained
 in pre-clinical or clinical studies may not be indicative of results that will
 be obtained in future clinical trials, and lack of success or delays in the
 initiation or completion of clinical trials may occur as a result of many
 factors.  Further examples of such risks and uncertainties also include, but
 are not limited to: the obtaining of sufficient financing to maintain the
 Company's planned operations; timely development, receipt of necessary
 regulatory approvals, and acceptance of new products; the successful
 application of the Company's technology to produce new products; the obtaining
 of proprietary protection for any such technology and products; the impact of
 competitive products and pricing and reimbursement policies; and changing
 market conditions.  The Company does not undertake to update forward-looking
 statements.  Although the Company believes that the forward-looking statements
 contained herein are reasonable, it can give no assurances that the Company's
 expectations are correct.  All forward-looking statements are expressly
 qualified in their entirety by this cautionary statement and other factors
 detailed in the Company's reports filed with the Securities and Exchange
 Commission.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X20932507
 
 

SOURCE  Genta Incorporated

    BERKELEY HEIGHTS, N.J., April 26 /PRNewswire Interactive News Release/ --
 Genta Incorporated (Nasdaq:   GNTA) reported that Dr. Robert E. Klem,
 Vice-President and Chief Technical Officer, delivered the keynote address
 today at the TIDES Oligonucleotide and Peptide Technology Conference this
 morning in Tucson, AZ.  In his presentation, Dr. Klem updated preclinical,
 clinical, and manufacturing issues regarding Genta's second and third
 generation oligonucleotide research programs, which encompass drugs that use
 both antisense and "decoy" mechanisms.
     Regarding the clinical program for Genasense(TM), Genta's lead antisense
 drug, Dr. Klem noted: "Patient accrual to our lead studies is strong, which
 reflects both high investigator enthusiasm and strong interest by the medical
 community.  We continue to anticipate completing enrollment in the melanoma
 study later this year.  Although I perceive that external interest has mostly
 focused on our melanoma trial, in fact our other lead programs may also
 conclude on roughly the same timeline.  Thus, at this point, I believe our
 first NDA for Genasense(TM) -- which remains on track for filing during the
 first half of 2002 -- could be submitted from any one of our 'registration
 quality' programs."
     Regarding manufacturing issues, Dr. Klem observed: "In our clinical
 development program and looking forward to next year's anticipated launch of
 Genasense(TM), Genta is strongly advantaged by our strategic partnership with
 the Life Sciences group at Avecia Ltd., the world's largest manufacturer of
 such compounds.  Manufacturing quality has been a key issue for FDA, and as
 the company with the first antisense product intended for systemic use, Genta
 has anticipated a high level of regulatory scrutiny.  We are very pleased with
 the Avecia collaboration, and both parties remain committed to establishing
 the highest quality standards in our manufacturing processes of this product."
     Genta Incorporated is a biopharmaceutical company with a diversified
 product portfolio that is focused on anticancer therapy.  Genasense(TM), the
 Company's lead antisense compound, is currently in several Phase 3 clinical
 trials.  Genta's product pipeline also comprises a portfolio of small
 molecules, including gallium-containing compounds for treatment of diseases
 associated with accelerated bone loss, and Androgenics compounds for prostate
 cancer.  Genta aims to become a direct marketer of its pharmaceutical products
 in the United States.  For more information about Genta, please visit their
 website at: http://www.genta.com.
 
     The statements contained in this press release that are not historical are
 forward-looking statements within the meaning of Section 27A of the Securities
 Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
 1934, as amended, including statements regarding the expectations, beliefs,
 intentions or strategies regarding the future.  Without limiting the
 foregoing, the words "anticipates," "believes," "expects," "intends," "may"
 and "plans" and similar expressions are intended to identify forward-looking
 statements.  The Company intends that all forward-looking statements be
 subject to the safe harbor provisions of the Private Securities Litigation
 Reform Act of 1995.  These forward-looking statements reflect the Company's
 views as of the date they are made with respect to future events, but are
 subject to many risks and uncertainties, which could cause the actual results
 of the Company to differ materially from any future results expressed or
 implied by such forward-looking statements.  For example, the results obtained
 in pre-clinical or clinical studies may not be indicative of results that will
 be obtained in future clinical trials, and lack of success or delays in the
 initiation or completion of clinical trials may occur as a result of many
 factors.  Further examples of such risks and uncertainties also include, but
 are not limited to: the obtaining of sufficient financing to maintain the
 Company's planned operations; timely development, receipt of necessary
 regulatory approvals, and acceptance of new products; the successful
 application of the Company's technology to produce new products; the obtaining
 of proprietary protection for any such technology and products; the impact of
 competitive products and pricing and reimbursement policies; and changing
 market conditions.  The Company does not undertake to update forward-looking
 statements.  Although the Company believes that the forward-looking statements
 contained herein are reasonable, it can give no assurances that the Company's
 expectations are correct.  All forward-looking statements are expressly
 qualified in their entirety by this cautionary statement and other factors
 detailed in the Company's reports filed with the Securities and Exchange
 Commission.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X20932507
 
 SOURCE  Genta Incorporated